Purinergic Signaling in the Cardiovascular System

Area of Science:

• Cardiovascular Physiology and Pharmacology
• Neuroscience
• Cellular Signaling

Background:

• Adenosine triphosphate (ATP) serves as a cotransmitter in various nerve pathways, including sympathetic, parasympathetic, and sensory-motor nerves, as well as within intracardiac neurons, highlighting its role in nervous control of the heart.
• Purinergic signaling, involving adenine nucleotides and nucleosides acting on purinoceptors, is integral to cardiovascular regulation, affecting cardiomyocytes, nodes, fibroblasts, and blood vessels.
• ATP plays a dual role in vascular tone regulation: vasoconstriction via sympathetic nerve release acting on P2X1 receptors and vasodilation mediated by endothelial cell ATP release in response to blood flow or hypoxia.

Purpose of the Study:

• To elucidate the multifaceted roles of purinergic signaling in cardiovascular physiology and pathophysiology.
• To explore the involvement of ATP and its receptors in regulating heart function, vascular tone, and blood cell activity.
• To discuss the therapeutic implications of purinergic signaling in a wide range of cardiovascular diseases.

Main Methods:

• Review and synthesis of existing literature on purinergic signaling in the cardiovascular system.
• Analysis of the mechanisms by which ATP and its receptors influence cardiac and vascular cells.
• Examination of the role of purinergic signaling in blood cells like erythrocytes and platelets.
• Investigation of the long-term effects of purine and pyrimidine nucleosides/nucleotides on vascular cells during processes like angiogenesis and restenosis.

Main Results:

• ATP is a key cotransmitter in cardiac autonomic and sensory nerves, influencing heart rate and contractility.
• Purinergic signaling regulates vascular tone through distinct mechanisms involving sympathetic nerves and endothelial cells.
• ATP and purinoceptors are critical for platelet aggregation and have trophic effects on vascular cells, influencing vessel remodeling.
• Purinergic signaling is implicated in the pathophysiology of numerous cardiovascular conditions, including heart failure, ischemia, and atherosclerosis.

Conclusions:

• Purinergic signaling, mediated by ATP and its receptors, is a fundamental aspect of cardiovascular regulation.
• Dysregulation of purinergic pathways contributes to cardiovascular diseases, presenting potential therapeutic targets.
• Targeting purinergic signaling offers a promising strategy for managing various cardiovascular pathologies, from thrombosis to heart failure.